105,000 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Acquired by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. purchased a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $897,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of OCUL. Mirae Asset Global Investments Co. Ltd. increased its holdings in Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 1,015 shares during the period. Capital Performance Advisors LLP acquired a new position in Ocular Therapeutix in the 3rd quarter worth approximately $70,000. Palumbo Wealth Management LLC acquired a new position in Ocular Therapeutix in the 4th quarter worth approximately $100,000. Creative Planning acquired a new position in Ocular Therapeutix in the 3rd quarter worth approximately $182,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Ocular Therapeutix by 64.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 29,989 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 11,793 shares during the period. Institutional investors and hedge funds own 59.21% of the company’s stock.

Insider Activity

In other news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the transaction, the insider now owns 269,059 shares in the company, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Donald Notman sold 11,119 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the transaction, the insider now owns 193,444 shares in the company, valued at $1,510,797.64. This trade represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,368 shares of company stock worth $162,801 in the last quarter. Corporate insiders own 3.50% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL opened at $7.25 on Friday. Ocular Therapeutix, Inc. has a 12 month low of $4.06 and a 12 month high of $11.77. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -5.49 and a beta of 1.22. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The firm’s 50 day simple moving average is $8.11 and its 200-day simple moving average is $8.95.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.